Navigation Links
Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
Date:2/28/2011

look forward to completing the follow-up of this initial study and to working with Sangamo as it expands these studies to include the full range of HIV-infected populations."

About SB-728-T

SB-728-T is an autologous CD4+ T-cell product modified with Sangamo's ZFN technology to specifically and permanently modify the cell's own DNA sequence encoding CCR5. CCR5 is the major co-receptor used by HIV to infect cells. A naturally occurring mutation of the CCR5 gene, CCR5-delta32, has been shown to provide protection against HIV infection. Sangamo scientists have demonstrated that CCR5-specific ZFNs can be used to disrupt the CCR5 gene and make human CD4+ T-cells resistant to HIV infection.  Sangamo's SB-728-902 Phase 1 study is designed to evaluate single escalating doses of SB-728-T in subjects that have sub-optimal CD4+ T-cell counts despite long-term HAART and no detectable viral load.  This group represents approximately thirty percent of all HIV-infected patients in the US.  The trial has recently been expanded to add an additional cohort of subjects that are failing HAART and have active viral infections.  In addition, Sangamo has an ongoing Phase 1 / 2 clinical trial, SB-728-1002, in HIV-infected subjects that are viremic but not currently on HAART.  

"While preliminary, these data are very encouraging and an early validation of the feasibility of our novel gene modification approach for the treatment of HIV/AIDS," said Dale Ando, M.D, Sangamo's vice president of therapeutic development and chief medical officer. "The SB-728-902 trial was designed to provide answers to several important questions.  We have confirmed that we have a scalable manufacturing process and that from a single apheresis we can manufacture doses of SB-728-T of 10 to 30 billion cells. We have also learned that a single infusion of these cells is well-tolerated and that the cells engraft, multiply and persist in the body.  The modi
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014  ConvaTec, a privately-held medical products and technologies ... Interim Chief Executive Officer of the company, effective December ... Berger .  "The Board of Directors of ConvaTec thanks ... the past three years," said Magnus Lundberg , ... confident that the company is well positioned for the ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 /PRNewswire/ ... Auxilium Pharmaceuticals, Inc. today announced that the Committee for ... Medicines Agency (EMA) has adopted a positive opinion for ... treatment of adult men with Peyronie,s disease with a ... degrees at the start of therapy. The ...
(Date:12/22/2014)... 2014  Mark Farrah Associates (MFA), www.markfarrah.com ... of the 2015 marketplace exchange projections and insights ... According to a recent ASPE (Office of ... of Health and Human Services) report, an estimated ... plans through the Marketplace as of October 2014 ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Insights into the Marketplace and Individual Market Growth 2
... progression reduced by 40 percent compared,to delayed treatment ... Pharma AG,Germany, announced today new data, which show ... with a first event suggestive of multiple sclerosis ... as measured by the Expanded Disability Status Scale,(EDSS) ...
... in Primate Study, CHICAGO, May 02, 2007 /PRNewswire-FirstCall/ ... its novel respiratory,antibiotic, Cethromycin, was shown to be ... reached from a,primate study where a 30-day course ... dose of inhaled anthrax as compared to,the standard ...
Cached Medicine Technology:Immediate Treatment of Early MS Patients with Betaferon,Significantly Delayed Permanent Disability 2Immediate Treatment of Early MS Patients with Betaferon,Significantly Delayed Permanent Disability 3Immediate Treatment of Early MS Patients with Betaferon,Significantly Delayed Permanent Disability 4Cethromycin Shown Effective Against Anthrax in Study 2Cethromycin Shown Effective Against Anthrax in Study 3Cethromycin Shown Effective Against Anthrax in Study 4
(Date:12/22/2014)... December 22, 2014 Physicians in China ... for the treatment of non-Hodgkin’s lymphoma (NHL), according to ... leading global healthcare consulting firm. MabThera is the only ... the most common form of NHL. , According to ... Barriers,” the incidence of NHL in China has been ...
(Date:12/22/2014)... 22, 2014 Give a loved one ... gift of health and vitality. , For a limited ... top-selling anti-aging formulas in special Holiday Wellness gift packages ... , Each bottle contains cutting-edge, proven nutritional support ... work as well as we age. , ...
(Date:12/22/2014)... 7,178 small business owners and marketing professionals ... and opted instead to join Digital Marketer, an Austin, ... 5th annual “Black Friday Boot Camp”. , ... the 5 hour online training event and raised $50,000 ... two Central Texas based charities dedicated to fighting childhood ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 NAPW ... 2014 Professional Woman of the Year. She is recognized ... the largest, most recognized networking organization of professional women ... the National Association of Professional Women is a vibrant ... Local Chapters. , Ms. Kreider is passionate and committed ...
(Date:12/21/2014)... 2014 In this report, the ... power source, product, and application. The market, by ... pneumatic instruments. By product, the market covers the ... The handpieces market is further subdivided into drills, ... laparoscopic instruments, shavers, wire/pin drivers, and others. Moreover, ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... (HealthDay News) -- A protein that regulates prostate stem cell ... healthy cells into prostate cancer cells has been identified by ... could prove important in efforts to find ways to control ... the University of California, Los Angeles. Previous research had ...
... News) -- The impending extinction of various plant and ... against the transmission of infectious disease, new research suggests. ... Science Foundation and National Institutes of Health,s Ecology of ... Agency, focused on how the loss of biodiversity might ...
... the manufacturing industry because the processing and dispensing of ... on an understanding of the physical properties and behaviours ... in Nature Communications by Dr Michael Smith ... at the University of Edinburgh and Politecnico di Torino, ...
... 2, 2010 (BRONX, NY) Nearly a quarter of ... higher cancer mortality rates than urban and suburban areas. Among ... percent of physicians practice in rural areas and almost 4 ... hour from an urban area. Finding the time, ...
... Reinberg HealthDay Reporter , THURSDAY, Dec. 2 ... your risk for first-time stroke by 80 percent, according ... the American Stroke Association. Also, as more Americans ... doctors are in a position to identify those at ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, ... U.S. Department of Health and Human Services (HHS) has announced ... health, including making dents in rates of obesity, smoking and ... Healthy People is to try to move the nation to ...
Cached Medicine News:Health News:Species Extinctions May Spell Trouble for Human Health 2Health News:Smashing fluids: The physics of flow 2Health News:ALBERT EINSTEIN COLLEGE OF MEDICINE HELPS ADDRESS NEED FOR IMPROVED CANCER CARE IN RURAL AMERICA 2Health News:Lifestyle Key to Preventing Stroke, Guidelines Say 2Health News:U.S. Government Sets New Health Goals for 2020 2Health News:U.S. Government Sets New Health Goals for 2020 3
... TOPS is a support catheter which assists ... angioplasty or stenting. The spiral catheter offers ... with .014 to .018 steerable guidewires to ... occlusion is crossed, TOPS is withdrawn while ...
... are indicated for the removal ... thrombi from vessels in the ... also be used for temporary ... of fluids, and blood sampling. ...
Introduced more than 30 years ago by Dr. Thomas J. Fogarty, these embolectomy catheters are indicated for the removal of fresh, soft emboli and thrombi from vessels in the arterial system....
The new XMI catheter incorporates the best in catheter technology to ,provide exceptional handling characteristics comparable to todays balloon catheters and stent delivery systems....
Medicine Products: